Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Celltex AdMSCs
- Development stage
- Phase 2
- Lead developer
- Celltex Therapeutics
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
Celltex AdMSCs are a cell therapy product consisting of culture-expanded mesenchymal stem cells (MSCs) derived from adipose (fat) tissue. Developed by Celltex Therapeutics Corporation, these cells are isolated from either the patient's own tissue (autologous) or from a donor (allogeneic) and expanded in a specialized laboratory environment to reach therapeutic quantities. MSCs are characterized by their multipotency and potent immunomodulatory properties. Once administered, typically via intravenous infusion, they migrate to sites of inflammation and injury where they secrete a variety of bioactive molecules, including cytokines, chemokines, and growth factors. This paracrine signaling helps to suppress excessive immune responses, reduce systemic inflammation, and promote endogenous tissue repair and regeneration. The product has been investigated in clinical trials for inflammatory and degenerative conditions such as rheumatoid arthritis and severe respiratory complications associated with COVID-19.
- Brand names
- Celltex AdMSCs
- Other names
- Adipose-derived mesenchymal stem cellsAdipose tissue-derived mesenchymal stem cellsAdMSCsCelltex stem cells
Beyond the preview
Go deeper on Celltex AdMSCs.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Celltex AdMSCs.